RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ReNeuron Group Stock

ReNeuron Group Stocks 2024

ReNeuron Group Stocks

57.13 M

Ticker

RENE.L

ISIN

GB00BF5G6K95

WKN

A2JBKZ

In 2024, ReNeuron Group had 57.13 M outstanding stocks, a 0% change from the 57.13 M stocks in the previous year.

The ReNeuron Group Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2026e57.13
2025e57.13
2024e57.13
202357.13
202256.98
202139.13
202032.67
201932.5
201832.5
201732.5
201626.8
201518.37
201414.63
20137.69
20126.41
20115.03
20103.38
20091.59
20081.54
20071.1
20060.75
20050.37
20040.37

ReNeuron Group shares outstanding

The number of shares was ReNeuron Group in 2023 — This indicates how many shares 57.13 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ReNeuron Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ReNeuron Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ReNeuron Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ReNeuron Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ReNeuron Group Aktienanalyse

What does ReNeuron Group do?

The ReNeuron Group PLC is a British biopharmaceutical company specializing in the development of novel therapies for the treatment of neurological diseases such as stroke, Parkinson's, and spinal cord injuries. It was founded in 1997 and is headquartered in Guildford, Surrey. ReNeuron initially focused on researching stem cells, particularly neural stem cells, to use them for the regeneration of nerve tissue. This innovative method was intended to revolutionize the treatment of brain and spinal cord injuries. In 2006, the company successfully developed and conducted clinical trials on the first neural stem cell therapy candidate. However, the development of cellular therapies posed challenges, particularly in terms of product safety and efficacy. Therefore, ReNeuron adjusted its business strategy and has since been working on the development of exosomal products and bioproducts. Exosomes are small membrane vesicles secreted by cells. The proteins, nucleic acids, and lipids contained within them play a crucial role in cellular processes and could represent a new class of therapeutic agents. With these two new focuses, ReNeuron aims to continue being innovative and maintain its position as a leader in the biotech industry. The ReNeuron Group PLC is divided into three main areas: Core Business, NeuDiscovery, and Incubator. The Core Business is dedicated to the development and commercialization of novel therapeutic approaches for neurological diseases. The company works on the development of exosomal products, bioproducts, and cell-based therapies to aid in brain and spinal cord injuries. In developing these products, the company collaborates closely with leading research institutions, universities, and other biopharma companies. In NeuDiscovery, ReNeuron follows an "Open-Platform" strategy and provides external researchers with access to its exosomal drug library. The company expects this to lead to the discovery of new therapeutic approaches and the application of its own technology in other areas of medicine. Incubator is an internal initiative aimed at creating and supporting start-up biotech companies. The company offers its technology and expertise to this division and invests in promising projects. ReNeuron has also brought several significant products to the market in the past, including an experimental drug for the treatment of strokes based on neural stem cells. This therapeutic program has the potential to be a groundbreaking approach in stroke treatment, reducing the need for long-term medical interventions such as rehabilitation. Overall, ReNeuron is a strong force in the biotech industry and has the potential to revolutionize the face of medicine. The company has proven its ability to develop innovative and effective therapies while also adapting its business strategy to meet the regulations of the biopharmaceutical environment. ReNeuron Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating ReNeuron Group's Shares Outstanding

ReNeuron Group's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in ReNeuron Group’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding ReNeuron Group’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in ReNeuron Group’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about ReNeuron Group stock

How many stocks are there of ReNeuron Group?

The current number of stocks of ReNeuron Group is 57.13 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of ReNeuron Group are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of ReNeuron Group evolved in recent years?

The number of shares of ReNeuron Group has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. ReNeuron Group as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of ReNeuron Group?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does ReNeuron Group pay?

Over the past 12 months, ReNeuron Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReNeuron Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of ReNeuron Group?

The current dividend yield of ReNeuron Group is .

When does ReNeuron Group pay dividends?

ReNeuron Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReNeuron Group?

ReNeuron Group paid dividends every year for the past 0 years.

What is the dividend of ReNeuron Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReNeuron Group located?

ReNeuron Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReNeuron Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReNeuron Group from 10/6/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did ReNeuron Group pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of ReNeuron Group in the year 2023?

In the year 2023, ReNeuron Group distributed 0 GBP as dividends.

In which currency does ReNeuron Group pay out the dividend?

The dividends of ReNeuron Group are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ReNeuron Group

Our stock analysis for ReNeuron Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReNeuron Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.